positive fluid balance and hemodilution [3] . Novel biomarkers to improve the detection of early AKI and provision of early interventions are therefore a subject of intense contemporary interest [4] .
An ideal AKI biomarker should fulfill the characteristics listed in table 1 . The majority of novel AKI biomarkers described thus far have been measured in urine. Urinary diagnostics have advantages, including the noninvasive nature of sample collection, the reduced number of interfering proteins, and the increased specificity for kidney injury. However, disadvantages include the lack of samples from patients with severe oliguria, and potential changes in urinary biomarker concentrations induced by the hydration status and diuretic therapy. A commonly employed correction factor for urinary dilution is to express urinary biomarkers adjusted for urinary creatinine concentration in research studies. However, this correction may be inaccurate in the situation of AKI because: (a) creatinine production may be reduced in some forms of AKI, and (b) both plasma and urine creatinine kinetics are significantly altered in the early phases of AKI [5] . Plasma-based diagnostics have revolutionized many facets of medicine, in part due to the easy accessibility of samples. However, plasma biomarkers may be confounded by extrarenal sources as well as by subclinical changes in renal elimination. Thus, in the case of AKI, it is important and ideal to develop both urinary and plasma biomarkers.
Over the past decade, the application of unbiased functional genomic and proteomic technologies has identified a number of novel AKI biomarkers. Many represent the early stress response of the kidney to AKI, induced in the kidney tubules during the early damage phase, and serendipitously appear in the urine or plasma well before a change in serum creatinine is detected [6] . Many are being developed and validated as early noninvasive biomarkers for the prediction of AKI and its clinical outcomes in humans. This is a rapidly evolving field, and the current status of some of the most promising examples is shown in table 2 . The list is certainly not exhaustive, since new markers are being continually discovered and compared to the ones listed [7] .
The most widely studied and validated early biomarker of AKI in children is neutrophil gelatinase-associated lipocalin (NGAL) [8] . Following cardiac surgery, plasma or urine NGAL measurements in over 6,600 patients were predictive of AKI and its severity, with an overall area under the receiver operating characteristic curve of 0.8-0.82. Similar results were obtained in over 6,000 critically ill patients. In 972 patients undergoing kidney transplantation, NGAL measurements predicted a delayed graft function with an overall area under the receiver operating characteristic curve of 0.88. In all three settings, NGAL significantly improved the prediction of AKI risk over the clinical model alone [8] . A large multicenter pooled analysis of existing NGAL studies was recently published, confirming the utility of this marker for the early diagnosis of AKI and its adverse outcomes [9] .
A recent study examined a combination of biomarkers following cardiac surgery [10] . Urinary NGAL was increased in AKI patients within 2 h of bypass initiation, urine interleukin-18 (IL-18) and liver-type fatty acid binding protein (L-FABP) were increased within 6 h, and urine kidney injury molecule-1 (KIM-1) increased at the 12-hour time point. All markers correlated with AKI severity and clinical outcomes and improved the risk prediction for AKI over clinical models. Thus, they represent temporally sequential markers, and a panel of such biomarkers may therefore help establish the timing of the injury and plan appropriate therapies.
The concept of outcomes in 'biomarker-positive, creatinine-negative' patients has recently been explored [9, 11] . Two studies enrolling about 4,000 cardiac surgical, critically ill, or emergency department patients grouped subjects according to their NGAL and serum creatinine status. Both studies found that measurement of NGAL complemented the information obtained by measurement of serum creatinine levels in establishing the diagnosis of AKI and predicting the prognosis. A substantial proportion of patients (about 20%) had elevated NGAL levels even in the absence of loss of renal excretory function. This previously undetectable condition ('subclinical AKI') was associated with a 2-to 3-fold increased risk of death or the need for RRT compared to patients in whom levels of serum creatinine were not elevated. Notably, even in patients with a significant loss of renal function, measurement of tubule damage biomarker levels still added prognostic information, as patients with increased levels of NGAL and serum creatinine levels displayed by far the worst prognoses.
It is anticipated that novel biomarkers of early structural AKI ('acute kidney damage') will provide critical diagnostic and prognostic stratification and will complement functional markers such as serum creatinine [2] . Are they ready for prime time? The eminent speakers in this session tackled that very question. As can be gleaned from their individual presentations, AKI biomarkers are indeed ready for more rigorous testing and validation. Dr. Endre reviewed a number of limitations of the AKI biomarker studies performed to date, including the lack of a true 'gold standard' in this field, and suggested approaches to their further validation and implementation [12] . Dr. Kellum reviewed emerging candidate biomarkers of recovery following AKI [13] . Dr. Parikh reviewed the significant discoveries (including relationships with short-and long-term clinical outcomes) of the TRIBE consortium from their prospective, multicenter study of AKI biomarkers in patients undergoing cardiac surgery [14] . Dr. Wendon and Dr. Maisel discussed potential applications of new AKI damage biomarkers along with existing tools for the evaluation and management of patients with hepatorenal [15] and cardiorenal [16] syndromes, respectively. This should include large enough future studies that demonstrate: (a) the association between early structural biomarkers and hard outcomes such as dialysis, cardiovascular events, and death, both with and independent of functional markers, and (b) that randomization to a treatment for AKI based on high structural/damage biomarker levels results in an improvement in kidney function and amelioration of adverse clinical outcomes. Successful demonstration of these two types of studies will truly launch AKI biomarkers for routine clinical application.
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